Analysts Set MiMedx Group, Inc. (NASDAQ:MDXG) PT at $12.00

MiMedx Group, Inc. (NASDAQ:MDXG) has been assigned a consensus recommendation of “Buy” from the five research firms that are currently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $12.00.

Several brokerages recently weighed in on MDXG. Craig Hallum reduced their price target on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. StockNews.com raised shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st.

Institutional Investors Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. Headlands Technologies LLC purchased a new stake in MiMedx Group in the first quarter worth approximately $27,000. Isthmus Partners LLC grew its position in shares of MiMedx Group by 30.4% during the 2nd quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after acquiring an additional 91,714 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group during the 2nd quarter valued at $40,000. Quest Partners LLC bought a new stake in shares of MiMedx Group during the 2nd quarter valued at $81,000. Finally, Entropy Technologies LP bought a new stake in shares of MiMedx Group during the 1st quarter valued at $99,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

Shares of MDXG opened at $5.83 on Monday. The company has a market capitalization of $855.90 million, a P/E ratio of 13.25 and a beta of 1.98. The company has a quick ratio of 3.22, a current ratio of 3.85 and a debt-to-equity ratio of 0.11. The firm has a 50 day moving average of $6.53 and a 200 day moving average of $6.94. MiMedx Group has a twelve month low of $5.57 and a twelve month high of $9.27.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The company had revenue of $87.21 million during the quarter, compared to the consensus estimate of $88.44 million. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. As a group, equities research analysts anticipate that MiMedx Group will post 0.26 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.